A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : cyclosporine
Phase: Phase 2
Ages Eligible For Study:
- Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination. - At least one objective measurable or evaluable disease parameter. - Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy. - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. - Adequate renal function as indicated by creatinine <= 1.5 the upper limit of normal (ULN). - Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) <= 2x the upper limit of normal. - Total bilirubin <= 2x the upper limit of normal. - Age 18 or older.